Journal of Pharmaceutical Sciences and Drug Development

1. Introduction

Cancer poses a major challenge to development; it undermines socio-economic advances throughout the world. It is estimated that the number of patients with cancer would increase from 12.7 million in the year 2008 to 22.2 million by 2030. The Journal of Pharmaceutical Science and Drug Developement is conveniently placed in the scholarly communication milieu to help counter the menace of cancer by aiding the development of novel treatment strategies, by providing novel insights into the mechanisms underlying this complex disease.

2. Bibliographic Information

3. Aim& Scope

Journal of Pharmaceutical Science and Drug Developement strives to publish highest quality articles pertaining to clinical research, which are freely accessible to one and all. The scope of the journal encompasses topics including drug design, drug discovery, natural products, formulation, personalized medicine, testing the efficacy of drug molecule in vitro and in vivo, pharmacokinetics, pharmacogenomics, analytical sciences, nanotechnology, therapeutic aspects, quality control, optimization by medicinal chemistry, drug pharmacodynamics, evaluation of safety and toxicity of drug molecules, regulatory science as well as computational approaches

In order to create highly impactful and original content, the European Journal of Clinical Oncology has gathered an expert Editorial Board, comprising of illustrious scientists who ensure that each manuscript is fairly, but stringently peer-reviewed. The decision on all submitted manuscripts will be taken independent of nationality, academic degree and relationship of the author with the journal. Papers will be published approximately 7 days after acceptance.

4. Types of Manuscripts

4.1. Research

Research papers are based on novel researches. A research paper is a primary source of knowledge which includes the methods and results of a new study done by the authors. The kind of study may differ (it could have been an experiment, survey, interview, etc.), but in all cases, raw data have been achieved and analyzed by the authors, and conclusions drawn from the results of that analysis. Research articles follow a particular format.
Journal of Pharmaceutical Science and Drug Developementfollows this content structure for research study:

4.2. Short communication

A brief research work considered as Short communication by Lexis publisher and Journal of Pharmaceutical Science and Drug Developement. Structure of Short communication defined similar to a research paper.

Important note: If a manuscript is submitted as an original research with brief and scant data then the editorial boards may consider the article as a Short communication.

4.3. Review

4.4. Mini Review

The structure of a Mini Review is almost similar to that of a Review paper but generally it is concised to a word limit of 2200.

4.5. Case Report

A case report is a complete report of the symptoms, signs, diagnosis, treatment and follow-up of a specific patient. Case reports could cover a demographic outline of the patient, but generally explain an uncommon or novel occurrence. Some case reports also have a literature review of former reported cases.Journal of Pharmaceutical Science and Drug Developement follows this content structure for case report:

5. Article Processing Charges (APC) :

IOMC Publisher is a self-financed and does not receive funding from any institution/government. Hence, the Journal operates solely through processing charges we receive from the authors and some academic/corporate sponsors.

Average Article prorcessing time (APT) is 45 days

The basic article processing fee or manuscript handling cost is as per the price mentioned above on the other hand it may vary based on the extensive editing, colored effects, complex equations, extra elongation of no. of pages of the article, etc.

Note: This publication charges are also applicable to invited authors.

Fast Editorial Execution and Review Process (FEE-Review Process):

Journal of Pharmaceutical Sciences and Drug Development is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee.Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.

Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.

The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.

6. Publication Ethics

For publication ethics related information please visit Publication ethics & malpractice statement

7. Medical Ethics

7.1. Informed consent

In general, informed consent assumes that authors are legally able to make their own decisions. For informed consent to take place, the information that’s given must be understood. The informed consent process is meant to give patients ongoing explanations that will help them make informed decisions about whether to start or stay in a clinical trial. The most important part of this process is their everyday interaction and discussions with the research team and other medical staff before, during, and after the trial. The consent form can be a great tool to help get this conversation started. This is all done so that patients can make the best decision for him/her, and to be sure that they are able to choose freely whether to enroll in or stay in the study. Much of this information may be on the consent form itself, which also regularly describes that they can withdraw from the study at any time without penalty. Before, during, and even after the clinical trial, patients will have the chance to ask questions and voice their concerns. Informed consent for clinical trials goes on for as long as the research lasts, and even afterward. Also Lexispublisher andJournal of Pharmaceutical Science and Drug Developement confirmed and followed WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects.

7.2. FDA (Food and Drug Administration) approval

The Federal Food, Drug, and Cosmetic Act is the basic food and drug law of the U.S. With many revisions, it is the most extensive law of its kind in the world. The law is planned to assure the user that foods are pure and healthy, safe to eat, and produced under healthy conditions; that drugs and devices are safe and effective for their proposed uses; that cosmetics are safe and made from suitable ingredients; and that all labeling and packaging is truthful, informative, and not deceptive. The authors should only use FDA approved products for medical studies on humans.